The Spectrum of Allergic Rhinitis: Risk Factors and their Clinical Relevance.

IF 1.5 Q4 PHARMACOLOGY & PHARMACY
Hari Niwas, Priyanka Bansal, Bhavani Pentela, Avijit Mazumder
{"title":"The Spectrum of Allergic Rhinitis: Risk Factors and their Clinical Relevance.","authors":"Hari Niwas, Priyanka Bansal, Bhavani Pentela, Avijit Mazumder","doi":"10.2174/0127722708397912251001102439","DOIUrl":null,"url":null,"abstract":"<p><p>Allergic rhinitis (AR) is a common, chronic inflammatory disorder of the upper respiratory tract, primarily caused by exposure to environmental allergens such as pollen, dust mites, and mold. It has a substantial impact on daily life, often leading to sleep disruption, decreased productivity, and a heightened risk of asthma and other related conditions. The underlying mechanism of AR involves an IgE-mediated immune reaction, with both immediate and delayed inflammatory responses contributing to ongoing symptoms. AR can be classified into several types-seasonal, perennial, occupational, and drug-induced-which aids in its diagnosis and personalized management. Key risk factors include hereditary susceptibility, environmental pollution, and modern lifestyle factors. Diagnosis is typically based on a detailed medical history, skin prick testing, and serum IgE measurements. Treatment strategies involve the use of antihistamines, intranasal corticosteroids, and leukotriene receptor antagonists, complemented by allergen-specific immunotherapy and lifestyle modifications such as allergen avoidance. In recent years, advanced therapies like targeted biologics (e.g., dupilumab) and probiotic-based treatments have emerged, offering promising new avenues for patients with persistent or severe symptoms.</p>","PeriodicalId":29815,"journal":{"name":"Recent Advances in Inflammation & Allergy Drug Discovery","volume":" ","pages":""},"PeriodicalIF":1.5000,"publicationDate":"2025-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Recent Advances in Inflammation & Allergy Drug Discovery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0127722708397912251001102439","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Allergic rhinitis (AR) is a common, chronic inflammatory disorder of the upper respiratory tract, primarily caused by exposure to environmental allergens such as pollen, dust mites, and mold. It has a substantial impact on daily life, often leading to sleep disruption, decreased productivity, and a heightened risk of asthma and other related conditions. The underlying mechanism of AR involves an IgE-mediated immune reaction, with both immediate and delayed inflammatory responses contributing to ongoing symptoms. AR can be classified into several types-seasonal, perennial, occupational, and drug-induced-which aids in its diagnosis and personalized management. Key risk factors include hereditary susceptibility, environmental pollution, and modern lifestyle factors. Diagnosis is typically based on a detailed medical history, skin prick testing, and serum IgE measurements. Treatment strategies involve the use of antihistamines, intranasal corticosteroids, and leukotriene receptor antagonists, complemented by allergen-specific immunotherapy and lifestyle modifications such as allergen avoidance. In recent years, advanced therapies like targeted biologics (e.g., dupilumab) and probiotic-based treatments have emerged, offering promising new avenues for patients with persistent or severe symptoms.

变应性鼻炎的频谱:危险因素及其临床相关性。
过敏性鼻炎(AR)是一种常见的上呼吸道慢性炎症性疾病,主要由暴露于环境过敏原如花粉、尘螨和霉菌引起。它对日常生活有重大影响,经常导致睡眠中断,生产力下降,哮喘和其他相关疾病的风险增加。AR的潜在机制涉及ige介导的免疫反应,即时和延迟的炎症反应都有助于持续的症状。AR可分为季节性、多年性、职业性和药物诱发的几种类型,这有助于其诊断和个性化管理。主要的危险因素包括遗传易感性、环境污染和现代生活方式因素。诊断通常基于详细的病史、皮肤点刺试验和血清IgE测量。治疗策略包括使用抗组胺药、鼻内皮质类固醇和白三烯受体拮抗剂,辅以过敏原特异性免疫治疗和生活方式改变,如避免过敏原。近年来,诸如靶向生物制剂(如dupilumab)和基于益生菌的治疗等先进疗法已经出现,为持续或严重症状的患者提供了有希望的新途径。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.30
自引率
0.00%
发文量
33
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书